Risk factors associated with survival and acute and chronic GVHD after a URD transplant
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Overall survival | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 30/120 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 35/172 | 1.25 (0.73-2.14) | .42 |
| Cy/Flu/ATG | 18/66 | 1.49 (0.82-2.73) | .19 |
| Cy/ATG | 15/51 | 1.30 (0.69-2.43) | .41 |
| Age, y | |||
| <30 | 61/304 | 1.00 | |
| ≥30 | 37/105 | 1.98 (1.31-3.00) | .001 |
| ATG source | |||
| h-ATG | 29/112 | 1.00 | |
| r-ATG | 31/183 | 0.62 (0.36-1.04) | .07 |
| Grade II-IV acute GVHD | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 57/119 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 51/169 | 0.66 (0.39-1.14) | .14 |
| Cy/Flu/ATG | 17/66 | 0.49 (0.25-0.97) | .04 |
| Cy/ATG | 19/51 | 0.75 (0.38-1.49) | .41 |
| ATG source | |||
| h-ATG | 58/111 | 1.00 | |
| r-ATG | 43/182 | 0.39 (0.23-0.65) | <.001 |
| Chronic GVHD | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 47/120 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 64/171 | 1.01 (0.69-1.47) | .98 |
| Cy/Flu/ATG | 20/66 | 0.80 (0.47-1.35) | .39 |
| Cy/ATG | 16/51 | 0.70 (0.39-1.26) | .23 |
| Age, y | |||
| <30 | 99/303 | 1.00 | |
| ≥30 | 48/105 | 1.57 (1.11-2.23) | .01 |
| GVHD prophylaxis | |||
| CNI + methotrexate | 120/352 | 1.00 | |
| CNI alone /CNI + mycophenolate | 27/56 | 1.72 (1.13-2.61) | .01 |
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Overall survival | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 30/120 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 35/172 | 1.25 (0.73-2.14) | .42 |
| Cy/Flu/ATG | 18/66 | 1.49 (0.82-2.73) | .19 |
| Cy/ATG | 15/51 | 1.30 (0.69-2.43) | .41 |
| Age, y | |||
| <30 | 61/304 | 1.00 | |
| ≥30 | 37/105 | 1.98 (1.31-3.00) | .001 |
| ATG source | |||
| h-ATG | 29/112 | 1.00 | |
| r-ATG | 31/183 | 0.62 (0.36-1.04) | .07 |
| Grade II-IV acute GVHD | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 57/119 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 51/169 | 0.66 (0.39-1.14) | .14 |
| Cy/Flu/ATG | 17/66 | 0.49 (0.25-0.97) | .04 |
| Cy/ATG | 19/51 | 0.75 (0.38-1.49) | .41 |
| ATG source | |||
| h-ATG | 58/111 | 1.00 | |
| r-ATG | 43/182 | 0.39 (0.23-0.65) | <.001 |
| Chronic GVHD | |||
| Conditioning regimen | |||
| Cy/ATG/TBI 200 cGy | 47/120 | 1.00 | |
| Flu/Cy/ATG/TBI 200 cGy | 64/171 | 1.01 (0.69-1.47) | .98 |
| Cy/Flu/ATG | 20/66 | 0.80 (0.47-1.35) | .39 |
| Cy/ATG | 16/51 | 0.70 (0.39-1.26) | .23 |
| Age, y | |||
| <30 | 99/303 | 1.00 | |
| ≥30 | 48/105 | 1.57 (1.11-2.23) | .01 |
| GVHD prophylaxis | |||
| CNI + methotrexate | 120/352 | 1.00 | |
| CNI alone /CNI + mycophenolate | 27/56 | 1.72 (1.13-2.61) | .01 |